Unknown

Dataset Information

0

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.


ABSTRACT: Co-stimulatory and inhibitory receptors expressed by immune cells in the tumor microenvironment modulate the immune response and cancer progression. Their expression and regulation are still not fully characterized and a better understanding of these mechanisms is needed to improve current immunotherapies. Our previous work has identified a novel ligand/receptor pair, LLT1/CD161, that modulates immune responses. Here, we extensively characterize its expression in non-small cell lung cancer (NSCLC). We show that LLT1 expression is restricted to germinal center (GC) B cells within tertiary lymphoid structures (TLS), representing a new hallmark of the presence of active TLS in the tumor microenvironment. CD161-expressing immune cells are found at the vicinity of these structures, with a global enrichment of NSCLC tumors in CD161+ CD4+ and CD8+ T cells as compared to normal distant lung and peripheral blood. CD161+ CD4+ T cells are more activated and produce Th1-cytokines at a higher frequency than their matched CD161-negative counterparts. Interestingly, CD161+ CD4+ T cells highly express OX40 co-stimulatory receptor, less frequently 4-1BB, and display an activated but not completely exhausted PD-1-positive Tim-3-negative phenotype. Finally, a meta-analysis revealed a positive association of CLEC2D (coding for LLT1) and KLRB1 (coding for CD161) gene expression with favorable outcome in NSCLC, independently of the size of T and B cell infiltrates. These data are consistent with a positive impact of LLT1/CD161 on NSCLC patient survival, and make CD161-expressing CD4+ T cells ideal candidates for efficient anti-tumor recall responses.

SUBMITTER: Braud VM 

PROVIDER: S-EPMC5927544 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications


Co-stimulatory and inhibitory receptors expressed by immune cells in the tumor microenvironment modulate the immune response and cancer progression. Their expression and regulation are still not fully characterized and a better understanding of these mechanisms is needed to improve current immunotherapies. Our previous work has identified a novel ligand/receptor pair, LLT1/CD161, that modulates immune responses. Here, we extensively characterize its expression in non-small cell lung cancer (NSCL  ...[more]

Similar Datasets

| S-EPMC4760235 | biostudies-literature
| S-EPMC3129164 | biostudies-literature
2012-01-04 | GSE32222 | GEO
| S-EPMC3120860 | biostudies-literature
| S-EPMC6819903 | biostudies-literature
2024-06-01 | GSE226620 | GEO
| S-EPMC9169908 | biostudies-literature
2016-04-07 | E-GEOD-70468 | biostudies-arrayexpress
| S-EPMC6036554 | biostudies-other
2016-04-07 | GSE70468 | GEO